One Global Service Provider: Matrix Labs buy, ₹1 dividend

Company profile and why this filing matters

One Global Service Provider Ltd operates in life sciences and healthcare solutions, with offerings across mass screening, diagnostics, laboratory services, healthcare services, and home-based health screening. It supplies hospitals, healthcare professionals, and government bodies with medical devices and consumables, and also provides public health data analytics. In recent exchange filings, the company outlined a set of corporate actions that combine capital expansion, acquisitions, and shareholder approvals. The announcements matter because they involve equity issuance on a preferential basis, a controlling acquisition in two private entities, and a dividend proposal. They also include governance items such as related-party transaction approvals and trading window restrictions.

Board meeting on September 3, 2026: preferential issue on agenda

The company informed BSE Limited that its Board of Directors will meet on September 3, 2026. The agenda includes considering and potentially approving the issuance of equity shares or other securities on a preferential basis. The board is also expected to approve the draft notice of the upcoming Annual General Meeting (AGM) and address other routine items. The disclosure cites SEBI LODR Regulation 29. The company said any issuance would be subject to regulatory approvals and shareholder consent, in line with the Companies Act, 2013 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Trading window closure under insider trading rules

Alongside the board meeting notice, the company announced a trading window closure for designated persons and their immediate relatives. The window is closed immediately and will reopen 48 hours after the conclusion of the September 3, 2026 board meeting. Such restrictions are standard practice around price-sensitive decisions such as capital issuance, acquisitions, and board approvals. The disclosure clarifies the timing, which helps investors understand when internal stakeholders are restricted from trading.

34th AGM scheduled for September 29, 2026

One Global Service Provider scheduled its 34th AGM for September 29, 2026. Shareholders are expected to vote on multiple resolutions, including a final dividend for FY26 and approvals linked to the acquisition and equity issuance. The company indicated that the AGM will also consider items related to preferential allotment and material transactions. The set of resolutions brings together capital structure changes, a strategic acquisition, and governance approvals into one shareholder meeting cycle.

FY26 dividend: ₹1 per share proposed

The company has recommended a final dividend of ₹1 per share for FY26, subject to shareholder approval at the AGM. The filing also references a dividend yield of 0.19%. The current price referenced in the provided information is ₹532. Beyond the amount itself, the dividend proposal is part of the AGM agenda alongside major corporate actions, which means investors may assess it in the context of capital issuance and acquisition-related dilution.

Acquisition plan: 51% in two Matrix Labs entities

A key agenda item disclosed is the proposed acquisition of a controlling 51% stake in Matrix Labs Diagnocare Private Limited (MLDPL) and Matrix Labs Private Limited (MLPL). The Board approved the acquisition of 51% equity stake in both entities. The company structured the transaction as consideration other than cash, meaning it will not pay cash upfront but will issue its own equity to discharge the purchase consideration. The filing states that the transaction does not qualify as a related-party deal and that the promoter group had no prior interest in the target companies.

Preferential allotment via share swap: pricing and allotment details

To complete the share swap arrangement, the company plans to issue up to 7,15,040 fully paid-up equity shares of face value ₹10 each at an issue price of ₹553 per share (including premium). The issue price is stated to be based on the volume-weighted average price over the 10 trading days preceding the relevant date of August 28, 2026, and determined under Chapter V of the SEBI ICDR Regulations. The allotments disclosed include 6,01,760 shares to Mr. Suresh for MLDPL and 64,440 shares to Mr. Suresh for MLPL, totaling 6,66,200 shares. Ms. Nithya S is slated to receive 48,840 shares for MLDPL, representing 0.24% of the company, while Mr. Suresh’s post-allotment holding is described as 3.29% through 6,66,200 shares. One portion of the provided information mentions 48,480 shares for Ms. Nithya S, but other sections consistently state 48,840 shares.

Consideration disclosed: ₹39.54 crore total, split across entities

The company disclosed the consideration for the acquisitions and the aggregate value implied by the preferential issue. For MLDPL, consideration is stated as ₹35.98 crore, and for MLPL as ₹3.56 crore. The total consideration for both acquisitions is stated as ₹39.54 crore, and the same aggregate appears as ₹39,54,17,120 in rupee terms. In some places, the consideration for each target company is separately cited as ₹3.56 crore, but the later detailed breakup provides different values for MLDPL and MLPL. Based on the share issuance plan and the stated per-share issue price, the company describes the transaction as a non-cash share swap.

Authorised share capital increased to support issuance

To accommodate the equity issuance and support future capital requirements, the Board approved an increase in authorised share capital. The authorised share capital will rise from ₹25.05 crore (2,50,50,000 equity shares of ₹10 each) to ₹50.00 crore (5,00,00,000 equity shares of ₹10 each). This change is directly linked to the company’s ability to issue additional shares, including the preferential allotment for the Matrix Labs transactions. Shareholders typically need to approve such changes, making the AGM a key checkpoint for the capital plan.

Related-party transaction limit with Lifenity Health set at ₹500 crore

The AGM agenda also includes approval for material related-party transactions with Lifenity Health Limited (LHL). The filing notes that the Managing Director of One Global Service Provider serves as a non-executive director at LHL. The company proposed a transaction limit of ₹500 crore for FY27. The scope covers purchase and sale of goods, services, and assets, as stated in the disclosure.

Other corporate actions and recent exchange history

The company also announced appointments of statutory auditors and internal auditors, alongside the acquisition approvals and preferential issue plan. Separately, the filing notes that the company previously received BSE trading approval on March 3, 2026 for equity shares issued following its merger with Plus Care International Private Limited. The approval covered 1,24,38,296 equity shares of face value ₹10 each, which were made available for trading from March 4, 2026. The company has also announced the appointment of Niraj Chordia as CFO.

Key numbers and dates at a glance

Market impact and what investors can track next

The disclosures outline potential dilution through the preferential issue, but also specify that the equity issuance is used to fund a non-cash acquisition. Investors may track the shareholder voting outcomes at the September 29, 2026 AGM, particularly on the preferential allotment, the acquisition, and the authorised share capital increase. The proposed ₹500 crore related-party transaction limit for FY27 is another key governance item because it sets the ceiling for transactions with LHL across goods, services, and assets. The company has also highlighted compliance steps such as the trading window closure, and the issue pricing methodology linked to the 10-day volume-weighted average preceding August 28, 2026.

Conclusion

One Global Service Provider’s upcoming board meeting and AGM bring together a dividend proposal, a share-swap acquisition of controlling stakes in two Matrix Labs entities, and a step-up in authorised share capital. The next confirmed milestones are the September 3, 2026 board meeting decisions and shareholder voting at the September 29, 2026 AGM. Investors will watch exchange updates for the final resolutions and any regulatory or shareholder approvals required for the preferential issue and acquisition.